en · de · es · fr · pt
faq-desk.peptides1004.com › Faq › Background And Research Context — Quick Reference

Background And Research Context — Quick Reference

By Editorial Desk · published 2025-12-13 · last reviewed 2026-01-18 · Faq

Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-01-18. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Identity and Research Origin

AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Research and Regulatory Context

Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.

Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.

AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.

Related pages on this site

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.

Notes from published material

=== Mechanism of action === Clindamycin phosphate is a water-soluble ester of the semi-synthetic antibiotic clindamycin, which is synthesized from lincomycin. Like the macrolide antibiotics, it acts as a bacteriostatic agent by interfering with the 50S subunit of the ribosome of Cutibacterium acnes, inhibiting bacterial protein synthesis and preventing bacteria from replicating. C. acnes plays a role in the development of acne. Benzoyl peroxide also kills C. acnes, but by releasing free radical oxygen species, thus oxidizing bacterial proteins. Also, it dries out the area by reducing sebum production, prevents clogged pores, and is a keratolytic agent. Since benzoyl peroxide is an oxidizer, not an antibiotic, it is not subject to C. acnes resistance unlike clindamycin. Both ingredients have been shown to reduce the number of acne lesions with statistical significance.

== Toxicity and harm potential == NBOMe compounds are often associated with life-threatening toxicity and death. Studies on NBOMe family of compounds demonstrated that the substances exhibit neurotoxic and cardiotoxic activity. Reports of autonomic dysfunction remains prevalent with NBOMe compounds, with most individuals experiencing sympathomimetic toxicity such as vasoconstriction, hypertension and tachycardia in addition to hallucinations. Other symptoms of toxidrome include agitation or aggression, seizure, hyperthermia, diaphoresis, hypertonia, rhabdomyolysis, and death. Researchers report that NBOMe intoxication frequently display signs of serotonin syndrome. The likelihood of seizure is higher in NBOMes compared to other psychedelics. NBOMe and NBOHs are regularly sold as LSD in blotter papers, which have a bitter taste and different safety profiles. Despite high potency, recreational doses of LSD have only produced low incidents of acute toxicity. Fatalities involved in NBOMe intoxication suggest that a significant number of individuals ingested the substance which they believed was LSD, and researchers report that "users familiar with LSD may have a false sense of security when ingesting NBOMe inadvertently". While most fatalities are due to the physical effects of the drug, there have also been reports of death due to self-harm and suicide under the influence of the substance. Given limited documentation of NBOMe consumption, the long-term effects of the substance remain unknown. NBOMe compounds are not active orally, and are usually taken sublingually.

These early experiments with animal blood provoked a heated controversy in Britain and France. Finally, in 1668, the Royal Society and the French government both banned the procedure. The Vatican condemned these experiments in 1670. Blood transfusions fell into obscurity for the next 150 years.

Sources: en.wikipedia.org

Background from the literature

== Use == In agriculture and horticulture, lime sulfur is sold as a spray to control fungi, bacteria, and insects. On deciduous trees, it can be sprayed during the winter on the surface of the bark in high concentrations, but because lime sulfur can burn foliage, it must be heavily diluted before being sprayed onto herbaceous crops, especially during warm weather. Lime sulfur is approved for use on organic crops in the European Union and the United Kingdom. Bonsai enthusiasts use undiluted lime sulfur to bleach, sterilize, and preserve deadwood on bonsai trees while giving it an aged look. Rather than being sprayed over the entire tree, as in pesticidal use, lime sulfur is painted directly onto the exposed deadwood and is often colored with a small amount of dark paint to make it look more natural. Without added pigments, the lime sulfur solution bleaches wood to a bone-white color that takes time to weather and become natural-looking. In the very specific case of bonsai culture, if lime sulfur is carefully applied by hand with a small brush and does not come into direct contact with the leaves or needles, this technique can also be used on evergreen bonsai trees as well as other types of green trees. However, this does not apply to normal use on common trees with green leaves. Diluted solutions of lime sulfur (between 1:16 and 1:32) are also used as a dip for pets to help control ringworm (a fungus), mange, and other dermatoses and parasites. Undiluted lime sulfur is corrosive to the skin and eyes and can cause serious injury, such as blindness.

== Honors and awards == Pauling received numerous honorary degrees (around 47 by his death), starting with his alma mater in 1933, and including prestigious institutions like Cambridge University, Oxford University, Princeton University, Reed College, and Yale University. Awards and honors received during his career include the following:

In March 2010, the Center for Public Integrity released a report that Bush's administration had made more than 900 false pretenses in a two-year period about the alleged threat of Iraq against the United States, as his rationale to engage in war in Iraq.

The term supermolecule (or supramolecule) was introduced by Karl Lothar Wolf et al. (Übermoleküle) in 1937 to describe hydrogen-bonded acetic acid dimers. The term supermolecule is also used in biochemistry to describe complexes of biomolecules, such as peptides and oligonucleotides composed of multiple strands. Eventually, chemists applied these concepts to synthetic systems. One breakthrough came in the 1960s with the synthesis of the crown ethers by Charles J. Pedersen. Following this work, other researchers such as Donald J. Cram, Jean-Marie Lehn and Fritz Vögtle reported a variety of three-dimensional receptors, and throughout the 1980s research in the area gathered a rapid pace with concepts such as mechanically interlocked molecular architectures emerging. The influence of supramolecular chemistry was established by the 1987 Nobel Prize for Chemistry which was awarded to Donald J. Cram, Jean-Marie Lehn, and Charles J. Pedersen in recognition of their work in this area. The development of selective "host–guest" complexes in particular, in which a host molecule recognizes and selectively binds a certain guest, was cited as an important contribution.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Network